Mylan N.V. and Biocon Ltd. today announced the launch in Australia of Ogivri™ (trastuzumab), a biosimilar to Herceptin®1 (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
The close of Mylan’s deal to acquire Meda marks the beginning of another exciting chapter as we work to create better health for a better world.
See inside our passion, innovation and commitment.
Innovation is a part of who we are and the reason we see opportunity in every challenge.
Since 1981, AIDS, the acquired immunodeficiency syndrome caused by the human immunodeficiency virus (HIV), has resulted in an estimated 39 million deaths (WHO).
We have one global quality standard because we know where our priorities are. It all starts and ends with you.
Our philanthropic efforts help raise money, awareness and hope.
Mylan was named Pharmacists’ Choice for Outstanding Pharma Company at the recent 2018 PRIME awards. It is a humbling tribute to what has been an outstanding year for the company.
Mylan and World TeamTennis share a commitment to overcoming barriers to access and providing a healthier future for generations